Properties (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:chemicalFormula |
sulfonamide
C20H22N4O4S contains a sulfur atom contains a carbon chain contains a nitrogen atom contains a sulfonamide group contains an aromatic ring |
| gptkbp:clinicalTrials |
gptkb:Canada
gptkb:USA Europe Phase II promising |
| gptkbp:compatibleWith |
moderate
|
| gptkbp:competitors |
oncology market
|
| gptkbp:composedOf |
multi-step synthesis
|
| gptkbp:developedBy |
gptkb:University_of_Rhode_Island
|
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water |
| gptkbp:financial_aid |
stable under normal conditions
|
| gptkbp:future_plans |
clinical trials
|
| https://www.w3.org/2000/01/rdf-schema#label |
UR-82004
|
| gptkbp:interactsWith |
may interact with anticoagulants
may interact with other chemotherapeutics |
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:numberOfStudents |
4 hours
|
| gptkbp:patentAssignee |
gptkb:University_of_Rhode_Island
|
| gptkbp:patentStatus |
patented
|
| gptkbp:productionCompany |
under investigation
|
| gptkbp:regulatoryCompliance |
not yet approved
|
| gptkbp:research |
NIH
pharmaceutical companies private investors |
| gptkbp:research_areas |
cancer treatment
|
| gptkbp:researchFocus |
oncology
|
| gptkbp:researchInterest |
gptkb:Mayo_Clinic
gptkb:Johns_Hopkins_University gptkb:National_Cancer_Institute |
| gptkbp:route |
oral
intravenous |
| gptkbp:sideEffect |
fatigue
nausea hair loss |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
cancer patients
tumor cells |
| gptkbp:triggerType |
inhibits cell proliferation
|
| gptkbp:usedFor |
treatment of cancer
|
| gptkbp:wasEstablishedIn |
2004
|
| gptkbp:weight |
402.48 g/mol
|